Bluebird Bio (BLUE) is trading 14% higher at $6.76 today. While the Health Care sector is having a somewhat gloomy day in general, the company is rapidly outrunning it's peers.
- Bluebird bio's gene therapy Skysona has been approved by the FDA
- This is the most expensive gene therapy to date, costing $3 million per patient
- Bluebird is hoping to use this therapy to treat patients with severe genetic disorders
Bluebird Bio has been trading between a 52-week high of $17.85 and a 52-week low of $2.87. The stock has a market cap of $521 Million.
bluebird bio is pioneering gene therapy with purpose. From its Cambridge, Mass., headquarters, they're developing gene and cell therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond their labs, the company is working to positively disrupt the healthcare system to create access, transparency and education so that gene therapy can become available to all those who can benefit.